<i>Epimedium</i> attenuates neuroinflammation and ameliorates Alzheimer's disease through a KAT2B-dependent mechanism.

Overview

1. Basic Chinese Medicine School (Qihuang College), Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China

Abstract

Background: Alzheimer's disease (AD) is the leading cause of dementia worldwide, yet effective therapies for this neurodegenerative disorder remain scarce. Epimedium, a herb with a history of thousands of years in traditional Chinese medicine, exhibits diverse biological activities and holds potential therapeutic effects against Alzheimer's disease. However, studies on its modern pharmacological mechanisms remain relatively limited.

Methods: TCMSP and PubChem were used to retrieve Epimedium constituents, and SwissTargetPrediction was used to predict potential targets. GeneCards, OMIM, and GEO databases were used to identify targets associated with AD. The AD model was established by intragastric administration of AlCl3 combined with intraperitoneal injection of D-galactose, with the normal saline group serving as controls. Cognitive function was assessed by the Morris water maze, and histopathological changes were observed by H&E staining. ELISA detected IL-1β and TNF-α levels, and qRT-PCR detected KAT2B, NF-κB, IL-1β, and TNF-α expression.

Results: We identified 172 key targets, with KAT2B and ACACB determined as core genes through transcriptomic screening. In vivo studies showed that Epimedium significantly ameliorated cognitive deficits and alleviated histopathological damage in hippocampal neurons. Furthermore, Epimedium suppressed neuroinflammation by reducing IL-1β and TNF-α levels and modulated the mRNA expression of key targets (KAT2B, NF-κB) in the hippocampus.

Conclusion: Epimedium improves pathological alterations in the hippocampal tissue and alleviates cognitive and behavioral impairments in rats by modulating neuroinflammation through KAT2B, thereby providing a scientific basis for its potential application and development as a therapeutic agent.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data, not to its authors' code: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Data links

• ncbi.nlm.nih.gov/geo, NCBI; found in the acknowledgements

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 29 September 2026: the first record

Recorded: type, language, journal, volume, pages, dates, 6 authors, 6 keywords, 1 funder, 47 references.

Cite

This paper

Gao, J., Song, M. L., Liu, J., Jiang, Z., Li, W., & Chen, Y. (2026). <i>Epimedium</i> attenuates neuroinflammation and ameliorates Alzheimer's disease through a KAT2B-dependent mechanism. Frontiers in medicine, 13, 1811410. https://doi.org/10.3389/fmed.2026.1811410

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1186/s13195-026-02075-8

Physical exercise in combination with audiovisual stimulation alleviates cognitive and affective impairments in Alzheimer's disease model mice via restoring lysosomal membrane integrity.

Journal: Alzheimer's research & therapy

In common: Alzheimer's / dementia, cellular / molecular, 3 references

[2] doi:10.1038/s41514-026-00443-0 [code]

Network-based discovery of regulatory drivers of cognitive decline in alzheimer's disease.

Journal: npj aging

In common: Alzheimer's / dementia, 2 references

[3] doi:10.3390/ijms27114756

Multi-Omics Integration and Causal Inference Identify HSD17B1 as a Potential Nobiletin Target Linking Neurosteroid Metabolism to Alzheimer's Disease.

Journal: International journal of molecular sciences

In common: Alzheimer's / dementia, cellular / molecular, 2 references

[4] doi:10.1038/s41467-026-75862-4 [code]

Targeting m<sup>6</sup>A writer METTL3 with engineered nanovesicles reduces neuroinflammation in vitro and in vivo.

Journal: Nature communications

In common: cellular / molecular, 2 references

[5] doi:10.1038/s44318-026-00817-w

The C9orf72/SMCR8 complex maintains microglial homeostasis via RAB8A-ESCRT-mediated lysosomal repair.

Journal: The EMBO journal

In common: cellular / molecular, 2 references

[6] doi:10.1016/j.apsb.2026.07.009

Neutrophil-mediated BDNF delivery for the treatment of moderate to severe Alzheimer's disease.

Journal: Acta pharmaceutica Sinica. B

In common: Alzheimer's / dementia, 2 references

[7] doi:10.1111/ejn.70480 [code]

Astrocyte Proximity Protects Synapses From Human Amyloid-Beta Induced Degeneration in a Mouse Ex Vivo Model of Early Alzheimer's Disease.

Journal: The European journal of neuroscience

In common: histology / microscopy, Alzheimer's / dementia, cellular / molecular, 1 reference

[8] doi:10.1080/19490976.2026.2659393

<i>Blastocystis</i> sp. induces neurocognitive deficits in mice via p38 MAPK-mediated downregulation of NR4A1.

Journal: Gut microbes

In common: histology / microscopy, cellular / molecular, 1 reference

[9] doi:10.3389/fnagi.2026.1761218

Integrated transcriptomic profiling combined with <i>in vitro</i> validation reveals the involvement of TMEM140 in the link between periodontitis and brain aging.

Journal: Frontiers in aging neuroscience

In common: Alzheimer's / dementia, cellular / molecular, 1 reference

[10] doi:10.1016/j.isci.2026.117187 [code]

Functional and structural characterization of dendritic spine pathology in a mouse model of tauopathy.

Journal: iScience

In common: histology / microscopy, Alzheimer's / dementia, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.